



AN ICMR APPROVED LAB

Patient ID: SH4608582 Name: FADHIL RAFEEQ

Address: MANGALURU, KARNATAKA

Age: 20, Gender: M

Mobile Number: 8088024327

ICMR ID: 536040508

SRF ID: 02677-MAN-20211219095

Sample Collected: 03/12/2021

Result Approved: 04/12/2021

Report Generated: 04/12/2021 07:16

Report Status: FINAL

TEST REPORT

Test Method SARS CoV-2 Qualitative RT PCR

Specimen Type Nasopharyngeal and Oropharyngeal

Gene 1: ORF1ab

Gene 2: N

Result Negative

INTERPRETATION

RESULT	REMARKS
Positive	RNA Specific To SARS-COV-2 Detected
Negative	RNA Specific To SARS-COV-2 Not Detected
Inconclusive	A Repeat Sample Is Suggested In Case Of Clinical Suspicion
Non Diagnostic	Internal control not detected, samples need to be repeated

ABOUT SARS COV 2

LIMITATIONS

SARSCoV2, formerly known as 2019nCoV, is the causative agent of the coronavirus. Negative results do not preclude COVID19 and should not be used as the sole basis disease 2019 (COVID19). Main symptoms of the disease include fever, cough and for patient management decisions. Negative results must be combined with clinical shortness of breath. The virus is spread via persontoperson contact through observations, patient history, and epidemiological information. respiratory droplets produced when a person coughs or sneezes. The SARSCoV2 RNAPositive results but do not rule out bacterial infection or coinfection with other viruses is generally detectable in nasopharyngeal/oropharyngeal swabs during the acute 3. Optimum specimen types and timing for peak viral levels during infections caused by phase of infection. Positive results are indicative of active infection. Real Time PCR2019nCoV have not been determined. Collection of multiple specimens (types and time assay targets specific genes and can be used for diagnosis of SARSCoV2 virus points) from the same patient may be necessary to detect the virus.

assay targets specific genes and can be used for diagnosis of SARSCoV2 virus infection which contributes to severe upper respiratory distress, complications

4. If the virus mutates in the rRTPCR target region, 2019nCoV may may be detected less predictably. Inhibitors or other types of interfe

- 4. If the virus mutates in the rRTPCR target region, 2019nCoV may not be detected or may be detected less predictably. Inhibitors or other types of interference may produce a false negative result.
 5. The performance of this test has not been established for monitoring treatment of
- 5. The performance of this test has not been established for monitoring treatment of 2019nCoV infection.

Meshadastage

Dr. Megha Rastogi MBBS, MD-Microbiology Consultant Microbiologist Mandu 85

Dr. Nandu T. G. Ph. D

REFERENCES

- 1. Laboratory testing for coronavirus disease 2019 (COVID19) in suspected human cases. Interim guidance. World Health Organization.
- 2. Druce et al. JCM. 2011
- 3. N. Engl. J. Med. 2020, 382, 929-936

*DISCLAIMERS

- 1. This is only a professional opinion. Not for Medico legal purpose.
- 2. Please correlate clinically.

SPICE HEALTHCARE PRIVATE LIMITED